John M. Amatruda

Merck & Co., Inc., Rahway, NJ, USA (United States) — United States

Medicine · Health Sciences

48h-index6.3kcitations99works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Diet and metabolism studies(26), Metabolism, Diabetes, and Cancer(22), Pancreatic function and diabetes(21), Pharmacology and Obesity Treatment(21), Diabetes Treatment and Management(19)

Publications99 total

Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo‐controlled 54‐week trial in patients with type 2 diabetes (一项为期54周的对持续使用二甲双胍与罗格列酮联合治疗的2型糖尿病患者加用西格列汀治疗的有效性与安全性的随机安慰剂对照研究)*
Journal of Diabetes·2012· 40 cited
Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes
Journal of Diabetes Investigation·2011· 23 citedOpen Access
Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
Current Medical Research and Opinion·2011· 128 cited
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes
International Journal of Clinical Practice·2011· 51 cited
Dipeptidyl Peptidase-4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP-1
Clinical Pharmacology & Therapeutics·2010· 176 cited
A Randomized Trial of Lifestyle Modification and Taranabant for Maintaining Weight Loss Achieved With a Low‐Calorie Diet
Obesity·2010· 27 citedOpen Access
A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study
International Journal of Obesity·2010· 65 cited
Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study
International Journal of Clinical Practice·2010· 202 cited
A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study
International Journal of Obesity·2010· 84 cited
Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes
Diabetes Obesity and Metabolism·2010· 153 citedOpen Access
Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double‐blind trial
Diabetes Obesity and Metabolism·2010· 100 citedOpen Access
Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus
Endocrine Journal·2010· 97 citedOpen Access
A one‐year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes
Diabetes Obesity and Metabolism·2009· 53 cited
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
Diabetes Obesity and Metabolism·2009· 303 citedOpen Access
Potent and Selective Agonism of the Melanocortin Receptor 4 With MK-0493 Does Not Induce Weight Loss in Obese Human Subjects: Energy Intake Predicts Lack of Weight Loss Efficacy
Clinical Pharmacology & Therapeutics·2009· 83 cited
Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study
Current Medical Research and Opinion·2009· 127 cited
Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea
Diabetes Research and Clinical Practice·2008· 158 cited
Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis
BMC Endocrine Disorders·2008· 130 citedOpen Access
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency
Diabetes Obesity and Metabolism·2008· 238 cited
EFFECTS OF TARANABANT, A NOVEL CANNABINOID 1 RECEPTOR (CB-1R) INVERSE AGONIST, ON WEIGHT REDUCTION IN OBESE PATIENTS OVER 12 WEEKS
Atherosclerosis Supplements·2008· 3 cited
page 1 of 5Next →

Frequent Co-authors

Keith D. Kaufman(15), Steven B. Heymsfield(8), Bret J. Musser(7), Debora Williams‐Herman(7), Ngozi Erondu(7), Ira Gantz(6), Arthur I. Salhanick(6), Peter P. Stein(5), Dean H. Lockwood(5), Michael J. Davies(4), John A. Wagner(4), S Suryawanshi(4), Ronald B. Langdon(3), Juan Camilo Arjona Ferreira(3), Gary Herman(3), Keith Gottesdiener(3), George A. Bray(3), Ken Fujioka(3), R. Teng(3), Gregory T. Golm(3)